ANI Pharmaceuticals, Inc. (ANIP)
71.23
-0.76
(-1.06%)
USD |
NASDAQ |
Sep 04, 16:00
71.20
-0.03
(-0.04%)
After-Hours: 20:00
ANI Pharmaceuticals Research and Development Expense (Quarterly) : 14.75M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.75M |
| March 31, 2026 | 10.60M |
| December 31, 2025 | 12.26M |
| September 30, 2025 | 12.30M |
| June 30, 2025 | 16.54M |
| March 31, 2025 | 10.56M |
| December 31, 2024 | 16.65M |
| September 30, 2024 | 10.13M |
| June 30, 2024 | 7.296M |
| March 31, 2024 | 10.51M |
| December 31, 2023 | 9.867M |
| September 30, 2023 | 11.12M |
| June 30, 2023 | 7.374M |
| March 31, 2023 | 5.924M |
| December 31, 2022 | 5.222M |
| September 30, 2022 | 7.657M |
| June 30, 2022 | 4.165M |
| March 31, 2022 | 5.274M |
| December 31, 2021 | 3.14M |
| September 30, 2021 | 2.683M |
| June 30, 2021 | 3.32M |
| March 31, 2021 | 3.006M |
| December 31, 2020 | 6.671M |
| September 30, 2020 | 2.976M |
| June 30, 2020 | 6.671M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.95M |
| December 31, 2019 | 11.19M |
| September 30, 2019 | 5.177M |
| June 30, 2019 | 5.773M |
| March 31, 2019 | 4.373M |
| December 31, 2018 | 3.482M |
| September 30, 2018 | 4.667M |
| June 30, 2018 | 5.137M |
| March 31, 2018 | 2.102M |
| December 31, 2017 | 2.651M |
| September 30, 2017 | 2.634M |
| June 30, 2017 | 2.167M |
| March 31, 2017 | 1.618M |
| December 31, 2016 | 0.135M |
| September 30, 2016 | 1.041M |
| June 30, 2016 | 0.764M |
| March 31, 2016 | 0.966M |
| December 31, 2015 | 0.661M |
| September 30, 2015 | 0.815M |
| June 30, 2015 | 0.995M |
| March 31, 2015 | 0.403M |
| December 31, 2014 | 0.568M |
| September 30, 2014 | 0.883M |
| June 30, 2014 | 0.851M |
| March 31, 2014 | 0.376M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Liquidia Corp. | 16.88M |
| Elanco Animal Health, Inc. | 92.00M |
| Harmony Biosciences Holdings, Inc. | 46.60M |
| Corcept Therapeutics, Inc. | 53.89M |